thiotepa

Ligand id: 7622

Name: thiotepa

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: thiotepa

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 50.93
Molecular weight 189.05
XLogP 0.76
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Thiotepa was originally used as an antineoplastic agent for various malignancies, including breast and ovarian adenocarcinoma and papillary carcinoma of the urinary bladder. Additionally, it is designated as an orphan drug by both the European Medicines Agency (EMA) and US FDA (both in 2007) for use as a preparative treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation.
Mechanism Of Action and Pharmacodynamic Effects
Thiotepa is an organophosphorus compound that acts as a DNA alkylating agent. Alkylating agents inhibit tumour growth by cross-linking nucleotide bases in DNA double-helix strands. Drug treatment irreversibly interferes with DNA replication, RNA transcription and general disruption of nucleic acid function. This action causes cell death. A major side effect of most alkylating agents is bone marrow depression and myelosuppression. With thiotepa, this complication is utilised to clinical benefit to destroy haematopoietic progenitor cells in the bone marrow of patients requiring bone-marrow transplant.
External links